Background: A prospective study was carried out to assess the efficacy and patient tolerability of electromotive drug administration (EMDA) of local anesthetic (LA) for outpatient flexible cystoscopy biopsy and cystodiathermy of recurrent low grade, non-muscle invasive (G1–2pTa) transitional cell carcinoma of the bladder. Patients and Methods: Over a 24 month period, 31 patients with proven G1–2pTa bladder can-cer underwent 33 biopsy and cystodiathermy procedures for recurrences (≤ 5mm diameter; maximum of 3 tumors) using EMDA LA. Biopsy results, patient satisfaction and pain scores (0–10), recurrence and progression rates were recorded. Results: The median pain score was 1 and 94% of patients would choose EMDA LA again. There were no complications. A histological diagnosis was possible in 27/33 procedures. No patient had a recurrence at the site of cystodiathermy or disease progression. Conclusions: EMDA LA allows effective local anesthesia of the bladder and enables satisfactory biopsy and cystodiathermy of small bladder cancer recurrenc-es in an outpatient setting.

Keywords:
Electromotive drug administration, Local anesthesia, Superficial bladder tumors, Recurrence
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.